Single agents, or a combination of ICIs with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs), are the mainstay of metastatic disease, while more recently, a hypoxia inducible factor (HIF) inhibitor has been added to the effective therapies, along with the mammalian target of rapamycin (mTOR) inhibitors in the third-line setting [53]. This evidence concerns the gene MTOR and metastatic neoplasm.